To my knowledge there is still no independent analyst covering this stock.

For me this does not matter and for Don I think it is fairly clear that he is not looking to the markets for funding.

It all comes down to the next 3 months, the deal that Don and team have drummed up and probably, as condition of the deal, the successful completion of the FA analysis with it's current uncertainties.

There are many possibilities that have been discussed on this forum in terms of deal structures. I'd be very pleased with a solid (high value) CVR type deal on apabetalone (not all of RVX) but given the history that I have followed on this and other sites I think it is too early for that. Hope I'm wrong.

I find the posts on RVX-297 very exciting because it is an indication of the range of possibilities in the RVX epigenetic portfolio.

Happy Thanksgiving to the Canadian posters and readers. While there are some colour changes in Muskoka it's still very green up here.

Let us hope that Don and team pretty much have the harvest in the barn.

GLTA

Toinv